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PMS2 gene mutation results in DNA
mismatch repair system failure in a
case of adult granulosa cell tumor
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Abstract
Background: Granulosa cell tumors are rare ovarian malignancies. Their characteristics include unpredictable
indolent growth with malignant potential and late recurrence. Approximately 95% are of adult type. Recent
molecular studies have characterized the FOXL2 402C > G mutation in adult granulosa cell tumor. Our previous
case report showed that unique FOXL2 402C > G mutation and defective DNA mismatch repair system are
associated with the development of adult granulosa cell tumor.
Findings: In this study, the DNA sequences of four genes, MSH2, MLH1, MSH6, and PMS2, in the DNA mismatch
repair system were determined via direct sequencing to elucidate the exact mechanism for the development of
this granulosa cell tumor. The results showed that two missense germline mutations, T485K and N775L, inactivate
the PMS2 gene.
Conclusions: The results of this case study indicated that although FOXL2 402C > G mutation determines the
development of granulosa cell tumor, PMS2 mutation may be the initial driver of carcinogenesis.
Immunohistochemistry-based tumor testing for mismatch repair gene expression may be necessary for granulosa
cell tumors to determine their malignant potential or if they are part of Lynch syndrome.
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Introduction
There are three main types of ovarian cancer: sex cord-
stromal, epithelial, and germ cell [1]. Sex cord-stromal
tumors develop from gonadal stromal component and
represent about 8% of all ovarian tumors [2]. Among
them, 70% are granulosa cell tumors [3], characterized
by indolent growth with malignant potential [4] and late
recurrence, even after more than a decade [5]. There are
two distinct forms of granulosa cell tumor, adult and
juvenile, based primarily on clinical presentations and
histopathologic characteristics [6]. The adult form com-
prises about 95% of granulosa cell tumors and frequently
presents in postmenopausal women with uterine
bleeding [7]. The juvenile form is much more rare,
comprising only about 5% of granulosa cell tumors, and af-
fects young women in their first 3 decades of life [7]. Recent
studies have revealed that FOXL2 gene 402C >G (C134W)
mutation plays a key role in the pathogenesis of adult
granulosa cell tumor [5, 8].
In our previous study [9], we reported an 80-year-old
woman with a granulosa cell tumor arising from the
ovary. Molecular studies showed a heterozygous FOXL2
402C > G mutation in the tumor on direct gene se-
quencing. DNA replication error was demonstrated on
analysis of the lengths of CAG repeats in androgen
receptor gene, in addition to defective DNA mismatch
repair system. DNA mismatch repair system failure
appeared likely in this patient via genomic imbalances
determined on array comparative genomic hybridization
analysis. In this study, the DNA sequences of four genes,
MSH2, MLH1, MSH6, and PMS2, in the DNA mismatch
repair system were determined via direct sequencing to
elucidate the exact mechanism for the development of
this granulosa cell tumor.
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Genomic DNA was isolated from peripheral blood lym-
phocytes using the QIAamp DNA blood kit (QIAGEN
GmbH, Hilden, Germany). Somatic DNA was prepared
from sections of paraffin embedded tissue using the
QIAamp tissue kit (QIAGEN). DNA was finally dis-
solved in 100 μl of TE buffer (10 mM Tris-HCl, pH 8.0,
and 1 mM EDTA). Concentrations of the DNA stocks
were estimated by spectrophotometer. Each genomic
DNA sample was adjusted to 100 ng/μl to serve as a
template for subsequent analyses.
Polymerase chain reaction
The exons of four genes, MSH2, MLH1, MSH6, and
PMS2, were amplified in fragments using published
primers from Sequenom® Standard EpiPanel. The PCR
fragments were amplified in a Perkin-Elmer 2400 DNA
thermal cycler in a final volume of 30 μl containing one-
fold Qiagen PCR buffer [Tris-HCl, KCl, (NH4)2SO4,
15 mM MgCl2; pH 8.7 at 20 °C], one-fold Q-solution,
0.015 units/μl Taq DNA polymerase from Taq DNA
polymerase kit (Qiagen), 500 nM for each primer,
200 μM dGTP, dATP, dCTP and dTTP (Promega;
Madison, WI, USA) and 300 ng/μl template. The PCR
conditions were initial denaturation at 95 °C for 5 min,
followed by 35 cycles at 95 °C for 1 min, at annealing
temperature for 1 min, and at 72 °C for 2 min, with final
extension at 72 °C for 10 min.
Direct sequencing
PCR products were purified using QIA quick PCR
Purification kits (Qiagen GmbH., Hilden, Germany). The
purified PCR products were sequenced using the cycle-
sequencing method with fluorescently labeled dideoxy
chain terminators from ABI Prism kit (Applied Biosystems,
Taipei, Taiwan) in an ABI Prism 3100 automated DNA
sequencer, according to the distributor’s protocol. The
sequencing primers were the same as those for the preced-
ing PCRs. When a mutation was detected, the nucleotide
sequence was confirmed on both strands.
Results
The DNA sequences of four genes, MSH2, MLH1,
MSH6, and PMS2, in the DNA mismatch repair system
were determined via direct sequencing. We found five
point mutations in the exon region of PMS2 gene in the
DNA samples from paraffin-embedded tumor specimens
(Table 1). Among them, there were two missense muta-
tions. Threonine was nonconservatively substituted to
lysine via heterozygous mutation at codon 485 in
exon 11 (T485K), 26796C > A (Fig. 1a) and asparagine
was nonconservatively substituted to leucine via het-
erozygous mutation at codon 775 (N775L) in exon
14, 36398A > G (Fig. 1c). These two heterozygous loci
were also identified in lymphocytic DNA (Fig. 1b and d).
There were three silent mutations, with no change in
amino acid sequence. The mutations at codon 96 in exon
4, 10352C > T and codon 822 in exon 15, 40585 T >G
were heterozygous. A homozygous mutation was found at
codon 280 in exon 7, 16758C >G.
The DNA samples from paraffin-embedded tumor
specimens were negative for somatic mutations in the
exon regions of the other three genes, MSH2, MLH1,
and MSH6. There were nucleotide alterations in the
intron regions in almost all mismatch repair genes
(Table 2). However, splicing status was not affected.
These passenger mutations may be attributed to clonal
evolution during tumorigenesis.
Discussion
Forkhead box protein L2 is encoded by FOXL2 gene.
Many functions of this protein are associated with the fea-
tures of granulosa cell tumor [8], including estrogen re-
ceptor binding activity, positive regulation of luteinizing
hormone and follicle-stimulating hormone secretion, posi-
tive regulation of apoptotic process and granulosa cell
differentiation [10]. When mutated, granulosa cells may
be affected and tumor may grow without apoptosis. By
itself, this cannot explain why granulosa cell tumor has
malignant potential. PMS2, a gene responsible for Lynch
syndrome, previously referred to as hereditary non-
polyposis colorectal cancer, was mutated in this case of
granulosa cell tumor. Although granulosa cell tumor is
not a pathognomonic malignancy of Lynch syndrome, it
has been found in 2/74 ovarian cancers in Lynch syn-
drome family [11]. Therefore, a reasonable explanation for
our findings is that PSM2 mutation precedes FOXL2. This
indicates that late malignancy may be due to PSM2 and
not FOXL2 itself. Immunohistochemical study may be
needed for granulosa cell tumors to exclude Lynch
syndrome.
The MutLα heterodimer formed by mismatch repair
proteins MLH1 and PMS2 is a major component of the
mismatch repair complex, yet mutations in the PMS2
gene are rare in the etiology of Lynch syndrome [12].
Table 1 Nucleotide alterations in the exon regions of PMS2 gene
in the DNA mismatch repair system in granulosa cell tumor
Nucleotide Alteration Exon Codon Amino Acid Zygote
10352 C > T 4 96 Ala Heterozygote
16758 C > G 7 280 Ser Homozygote
26796 C > A 11 485 Thr > Lys Heterozygote
36398 A > G 14 775 Asn > Leu Heterozygote
40585 T > G 15 822 Leu Heterozygote
GenBank accession number NG_008466.1 for nucleotide and NP_000526 for
amino acid
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The missense variant N775L, which is located in the
MLH1 protein-interacting region, has not been previ-
ously reported. The nonconservative substitution of
asparagine to leucine might change the N-glycosylation
status of PMS2 protein. A previous study has illustrated
N-glycosylation changes in colorectal cancer tissues
when compared with accompanying control tissues [13].
The missense variant T485K is a rare polymorphism in
the general population [14].
Although granulosa cell tumors are very rare, their po-
tential for malignancy makes them clinically significant
and it is important to identify the molecular mechanisms
involved in their development [4]. A single genetic lesion
is rarely sufficient to promote tumorigenesis, but it does
Fig. 1 Partial sequencing chromatograms present the heterozygous T485K (26796 C > A, A, B) and N775L (36398 A > G, C, D) mutations in the
PMS2 gene. Nucleotide sequences were determined from granulosa cell tumor (a, c) and normal sample (peripheral blood lymphocytes, b, d).
Blue triangles indicate the positions of nucleotide numbers 26796 (M = A C) and 36398 (R = G A)
Table 2 Nucleotide alterations in the intron regions of four genes in the DNA mismatch repair system in granulosa cell tumor
Gene Nucleotide Alteration Zygote Intron GenBank
MLH1 37259 1 base (A) deletion Heterozygote 12 NG_007109.2
MLH1 59246 C > G Heterozygote 14 NG_007109.2
MSH2 10262 1 base (A) deletion Heterozygote 1 NG_007110.2
MSH2 16320 4 bases (AAAA) deletion Heterozygote 4 NG_007110.2
MSH2 65062 2 bases (AA) insertion Homozygote 9 NG_007110.2
MSH2 68697 G > A Heterozygote 10 NG_007110.2
MSH2 78202 1 base (A) deletion Homozygote 12 NG_007110.2
MSH2 78234 T > C Heterozygote 12 NG_007110.2
MSH6 5480 G > A Heterozygote 1 NG_007111.1
MSH6 25553 A > T Homozygote 5 NG_007111.1
MSH6 27596 4 bases (ATCT) deletion Homozygote 7 NG_007111.1
MSH6 28266 C > G Homozygote 8 NG_007111.1
PMS2 15016 A > G Heterozygote 6 NG_008466.1
PMS2 31112 G > A Heterozygote 11 NG_008466.1
PMS2 31334 A > G Heterozygote 12 NG_008466.1
PMS2 35294 T > C Heterozygote 12 NG_008466.1
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create a mutator phenotype which predisposes to add-
itional mutations involved in cancer development. The
PMS2 N775L mutation was identified in both lympho-
cyte and tumor in this study. The FOXL2 402C > G mu-
tation was observed in granulosa cell tumor, but not in
the blood or normal tissue [9]. Therefore, the tumor ex-
hibited both PMS2 and FOXL2 mutations, and PMS2
mutation occurred before FOXl2 mutation. The results
of this study indicated that the amino acid changing mu-
tation, N775L, in PMS2 gene may be the driver mutation
which induces DNA mismatch repair system failure.
Our hypothesis is that DNA mismatch repair system
failure induces FOXL2 402C > G mutation, leading to
granulosa cell tumor development [9]. The DNA mis-
match repair system failure randomly causes further
mutations of tumor suppressor genes or oncogenes,
resulting in late recurrence and unpredictable malignant
behavior of granulosa cell tumor [9].
The tumor spectrum in Lynch syndrome is associated
with germline mutations of DNA mismatch repair genes
involving 8 or more organ sites, such as colorectal,
endometrial and ovarian cancers [15]. Adrenal and go-
nadal steroidogenic cells share a common developmental
origin, adreno-genital primordium [16]. The develop-
ment of granulosa cell tumor may be similar to that of
adrenocortical carcinoma, a malignancy of steroidogenic
cells, which has been demonstrated to be associated with
Lynch syndrome [17]. We may add this special type of
ovarian tumor to Lynch syndrome, which may allow for
early detection and treatment. Immunohistochemistry-
based tumor testing for mismatch repair gene expression
may be necessary for granulosa cell tumor to determine
malignant potential or if part of Lynch syndrome [18].
This would provide accurate prognosis and prophylactic
information for patients with this type of tumor.
Although direct sequencing of affected genes is defini-
tive and identifies the specific mutation in a family,
mutations involving exon skipping or located outside the
amplified fragment may be missed on DNA-based
screening [14]. Moreover, granulosa cell tumors are rare.
It is necessary to test more granulosa cell tumor patients
for Lynch syndrome to evaluate the prevalence and
association of granulosa cell tumor and Lynch syndrome
in the future. A single case may not be adequate to de-
termine the exact cause of this type of tumor. More case
reports are required to understand the molecular
characteristics of these tumors, other than the FOXL2
gene, and elucidate their connections with mismatch
repair system.
Conclusions
The results of this case study indicated that although
FOXL2 402C > G mutation determines the development
of granulosa cell tumor, PMS2 N775L mutation may be
the initial driver of carcinogenesis. Early detection may
allow for better treatment of granulosa cell tumor.
Immunohistochemistry-based tumor testing for mis-
match repair gene expression may be necessary for
granulosa cell tumor for determining malignant
potential or if part of Lynch syndrome.
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